

1 **Tryptophan and arginine metabolism is significantly altered at the time of admission in**  
2 **hospital for severe COVID-19 patients: findings from longitudinal targeted metabolomics**  
3 **analysis**

4 **Running title:** Metabolomic profiling in severe COVID-19 patients.

5 **Laura Ansone<sup>\*a</sup> & Monta Ustinova<sup>\*a</sup>, Anna Terentjeva<sup>b</sup>, Ingus Perkons<sup>c</sup>, Liga Birzniece<sup>a</sup>,**  
6 **Vita Rovite<sup>a</sup>, Baiba Rozentale<sup>b</sup>, Ludmila Viksna<sup>b</sup>, Oksana Kolesova<sup>b</sup>, Kristaps Klavins<sup>d</sup>,**  
7 **Janis Klovins<sup>a#</sup>.**

8 <sup>a</sup>Latvian Biomedical Research and Study Centre, Ratsupites iela 1, Riga, Latvia, LV-1067.

9 <sup>b</sup>Riga Stradins University, Dzirciema iela 16, Riga, Latvia, LV-1007.

10 <sup>c</sup>Institute of Food Safety, Animal Health and Environment (BIOR), Lejupes iela 3, Riga, Latvia,  
11 LV-1076.

12 <sup>d</sup>Riga Technical University, Kalku iela 1, Riga, Latvia, LV-1658.

13 <sup>\*</sup>Laura Ansone and Monta Ustinova share the co-first authorship.

14 LA contributed in the sample analysis, patient recruitment process and sample collection, data  
15 analysis and interpretation, drafting the manuscript.

16 MU contributed in patient recruitment process and sample collection, data analysis and  
17 interpretation, funding acquisition, drafting the manuscript.

18 #Corresponding author: [Klovins@biomed.lu.lv](mailto:Klovins@biomed.lu.lv)

19 Word count for the abstract: 160

20 Word count for the main text: 1133

21

22

## 23 **Abstract**

24       The heterogeneity in severity and outcome of COVID-19 cases points out the urgent need  
25 for early molecular characterization of patients followed by risk-stratified care. The main  
26 objective of this study was to evaluate the fluctuations of serum metabolomic profiles of  
27 COVID-19 patients with severe illness during the different disease stages in a longitudinal  
28 manner. We demonstrate a distinct metabolomic signature in serum samples of 32 hospitalized  
29 patients at the acute phase compared to the recovery period, suggesting the tryptophan  
30 (tryptophan, kynurenine, and 3-hydroxy-DL-kynurenine) and arginine (citrulline and ornithine)  
31 metabolism as contributing pathways in the immune response to SARS-CoV-2 with a potential  
32 link to the clinical severity of the disease. In addition, we provide evidence for glutamine  
33 metabolism in M2 macrophages as a complementary process and contribution of phenylalanine  
34 and tyrosine in the molecular mechanisms underlying the severe course of the infection. In  
35 conclusion, our results provide several functional metabolic markers for disease progression and  
36 severe outcome with potential clinical application.

## 37 **Importance**

38       Although the host defense mechanisms against SARS-CoV-2 infection are still poorly  
39 described, they are of central importance in shaping the course of the disease and the possible  
40 outcome. Metabolomic profiling may complement the lacking knowledge of the molecular  
41 mechanisms underlying clinical manifestations and pathogenesis of COVID-19. Moreover, early  
42 identification of metabolomics-based biomarker signatures is proved to serve as an effective  
43 approach for the prediction of disease outcome. Here we provide the list of metabolites  
44 describing the severe, acute phase of the infection and bring the evidence of crucial metabolic

45 pathways linked to aggressive immune responses. Finally, we suggest metabolomic phenotyping  
46 as a promising method for developing personalized care strategies in COVID-19 patients.

#### 47 **Main text**

48 More than a year has passed since the World Health Organization (WHO) announced the  
49 COVID-19 outbreak as a pandemic in March 2020, following the rapid spread of the SARS-  
50 CoV-2 virus (1). The clinical course of COVID-19 is versatile, the infection of the SARS-CoV-2  
51 virus not only varies in its severity from asymptomatic or mild and moderate respiratory disease  
52 (80%) to clinically severe or critical life-threatening disease (20%) but also varies in a range of  
53 organs the disease can affect (2, 3). Diverse clinical trajectories seem to be the result of the  
54 immune response differences between individuals (4).

55 Multiple innate and adaptive immune system pathways that produce inflammatory  
56 molecules against the virus and virus-infected human cells are triggered after the SARS-CoV-2  
57 entry in the cell, with characteristic overexpression of proinflammatory cytokines (e.g. IL-6,  
58 TNF $\alpha$ , IFN- $\gamma$ ) known as cytokine storm in the most severe cases (4–6). The host's immune  
59 responses typically involve changes in metabolic processes at the cellular level, reflecting the  
60 host-defense mediators and underlying mechanisms (7).

61 Detailed understanding of the molecular mechanisms behind COVID-19 pathogenesis and  
62 inflammatory response is needed to predict and reduce individual risks, develop therapeutic  
63 strategies, and reduce the overall ~2% mortality rate (mortality in hospitalized patients can be up  
64 to 30%) (8, 9). The human blood sera metabolome (defined as small molecules <1500–2000 Da)  
65 reflects the organism's metabolic state and is widely used to gain a deeper understanding of the  
66 pathogenesis of diseases. Recent reports of metabolomics studies highlight the pivotal role of  
67 cellular metabolites in programming immune response to SARS-CoV-2 infection (10–13).

68 Considering the extremely high heterogeneity of the COVID-19 disease and lack of promising  
69 predictive biomarkers, we believe that implications of longitudinal metabolite profiling may be  
70 beneficial in understanding the underlying mechanisms of the diverse course of the disease and  
71 promote the early identification of people at increased risk of severe illness from COVID-19 and  
72 related complications.

73 We performed quantitative targeted metabolome analysis with liquid chromatography-  
74 mass spectrometry (LC-MS) in blood sera of 32 hospitalized COVID-19 patients at the acute  
75 phase (time of admission at the hospital) and the recovery phase ( $40 \pm 14.92$  days) of the disease  
76 (see Text S1 in the supplemental material for a detailed description of methods). Written  
77 informed consent was obtained from every participant before their inclusion in the study, and the  
78 study protocol was approved by the Central Medical Ethics Committee of Latvia (No. 01-  
79 29.1.2/928).

80 As expected, the clinical blood tests revealed abnormal hematological parameters for the  
81 majority of study participants at the time of hospitalization, with a high variation in platelet  
82 ( $202.94 \pm 65.26 \mu\text{L}$ ) levels and low lymphocyte measurements ( $0.64 \pm 0.56 \mu\text{L}$ ), which coincides  
83 with previously reported lymphopenia as the hallmark of severe COVID-19 cases. We also  
84 observed a high variation of several markers (e.g. alanine aminotransferase, bilirubin, lactate C-  
85 reactive protein) indicating renal and hepatic dysfunction, myocarditis, inflammation, and  
86 coagulation, which confirms the systemic response to the infection in our study cohort(2, 14)  
87 (see Table S1 in the supplemental material).

88 Out of 51 metabolites analyzed by LC-MS, 22 metabolites showed significantly altered  
89 levels (paired t-test,  $\text{FDR} < 0.05$ ) in the serum samples during the acute phase in comparison to  
90 the recovery phase (Table 1), where concentrations for 16 compounds were significantly

91 elevated, whereas 8 metabolites were decreased. The hierarchical clustering and principal  
92 component analysis of the obtained metabolomic profiles showed clear metabolomics-based  
93 discrimination of samples collected in different phases of the disease (Figure1. A and B),  
94 indicating an altered metabolic activity during infection. Pathway analysis revealed 13  
95 significantly enriched pathways (FDR<0.05), including phenylalanine, tyrosine and tryptophan  
96 biosynthesis, D-glutamine and D-glutamate metabolism and arginine biosynthesis (Figure1 C,  
97 Table S3). Statistical analysis was done with Metaboanalyst version 5.0 (15).

98 We found L-glutamine (Figure 1D) as the most significantly changed amino acid between  
99 the paired samples with reduced acute phase concentrations. It is known that glutamine  
100 deprivation and decreased glutaminolysis inhibits M2 macrophage polarization, which may  
101 partly explain the hyperinflammatory state in severe COVID-19 cases (16, 17). Moreover, the  
102 beneficial effect of glutamine has been proposed in multiple studies, where adding enteral L-  
103 glutamine to the regular nutrition shortened the duration of hospitalization and improved the  
104 outcome in moderate to severe COVID-19 cases (18, 19).

105 Two other amino acids involved in arginine catabolism through the Urea cycle: citrulline  
106 (Figure 1D) and ornithine (Table 1) were found to significantly change between the acute and  
107 recovery phases. However, alterations in the levels of L-arginine itself were not detected. Low  
108 blood plasma citrulline levels have already been reported in COVID-19 patients, whereas in  
109 patients with severe sepsis, the decreased citrulline levels are associated with acute respiratory  
110 distress syndrome (11, 13, 20). Since arginine can be metabolized to creatine and then to  
111 creatinine, both varying highly in our study cohort according to regular blood tests performed  
112 during hospitalization, arginine catabolism may be implicated in disturbed kidney function of  
113 COVID-19 patients (21).

114 Three out of 22 metabolites showing significantly changed levels between acute infection  
115 and recovery phase are involved in the tryptophan-kynurenine pathway: L-tryptophan,  
116 kynurenine, and 3-hydroxy-DL-kynurenine (Figure 1D, Table 1). The reduction of tryptophan  
117 levels and increase of kynurenine, 3-hydroxy-DL-kynurenine in the acute phase supports the  
118 conclusions of previous reports and confirms this pathway's key role in severe COVID-19 cases  
119 (10, 11). *In vitro* experiments have shown that tryptophan deprivation sensitizes T cells to  
120 apoptosis, inhibits proliferation of T cells, and plays a role in CD8 T-cell suppression in cancer  
121 (22, 23). Notably, the tryptophan-kynurenine pathway shows a modulatory effect on the  
122 macrophage-mediated responses by targeting the synthesis of the metabolic coenzyme  
123 NAD<sup>+</sup>(24, 25). According to Thomas *et al.* dysregulated tryptophan metabolism, an essential  
124 regulator of inflammation and immunity may be a potential explanation for severity in older  
125 COVID-19 patients (Thomas et al., 2020).

126 Finally, we observed a significant difference in L-phenylalanine (Figure 1D) and tyrosine  
127 levels in our cohort between the analyzed disease phases, both already suggested as metabolic  
128 hot spots of COVID-19 before (26). In sepsis and HIV-1 infection, the increased phenylalanine  
129 sera concentrations are linked to immune activation and increased cardiovascular event risk (27–  
130 29). Although the mechanisms behind this association are not well studied, it is in line with  
131 microvascular endothelial damage and higher coagulation risk characteristic to both: coronary  
132 heart disease and severe COVID-19 (29). Phenylalanine and tyrosine are catabolized to  
133 dopamine and epinephrine, and the latter has been employed in cardiac arrest as a result of  
134 cytokine storm, characteristic to severe COVID-19 patients(30).

135 In conclusion, our study shows that metabolomic profiling provides novel insights into the  
136 pathogenesis of host-defense mechanisms and may be further applied for rapid biomarker

137 discovery in infectious disease. These discoveries could show novel therapeutic strategies as  
138 indirect targets to fasten the recovery process after severe COVID-19. To the best of our  
139 knowledge, this is the first longitudinal study covering metabolomic profiling of severe COVID-  
140 19 patients.

#### 141 **Data availability**

142 The raw data supporting the current study are available from the corresponding author on  
143 request.

#### 144 **Acknowledgments**

145 This study is funded by the Ministry of Education and Science, Republic of Latvia, project  
146 "Establishment of COVID-19 related biobank and integrated platform for research data in  
147 Latvia", project No. VPP-COVID-2020/1-0016.

148 We acknowledge The Boris and Inara Teterev Foundation for support to Riga Stradins  
149 University in patient sample collection.

150 The authors acknowledge the Latvian Biomedical Research and Study Centre and the Genome  
151 Database of the Latvian Population for providing the infrastructure, biological material, and data.

#### 152 **Author contributions**

153 LA, KK, IP, LB performed the sample analysis; MU, VR, LA, BR, LV, OK were involved in  
154 patient recruitment process and sample collection; AT ensured the clinical data acquisition; MU,  
155 LA drafted the manuscript; JK provided critical revision of the manuscript; LA, KK, MU  
156 performed the data analysis and interpretation; MU, JK collaborated in funding acquisition, JK

157 performed supervision and conceptualization of the study. All authors read and approved the  
158 final manuscript.

### 159 **Declaration of Interests**

160 The authors declare no competing interests.

### 161 **References**

- 162 1. World Health Organization. 2020. Coronavirus disease 2019 (COVID-19) Situation  
163 Report – 51.
- 164 2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei  
165 Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. 2020. Clinical course and risk  
166 factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective  
167 cohort study. *Lancet* 395:1054–1062.
- 168 3. Wu Z, McGoogan JM. 2020. Characteristics of and Important Lessons from the  
169 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of  
170 72314 Cases from the Chinese Center for Disease Control and Prevention. *JAMA - J Am*  
171 *Med Assoc* 323:1239–1242.
- 172 4. García LF. 2020. Immune Response , Inflammation , and the Clinical Spectrum of 11:4–8.
- 173 5. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian  
174 DS. 2020. Dysregulation of immune response in patients with coronavirus 2019 (COVID-  
175 19) in Wuhan, China. *Clin Infect Dis* 71:762–768.
- 176 6. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. 2020. COVID-  
177 19: consider cytokine storm syndromes and immunosuppression. *Lancet* 395:1033–1034.



- 178 7. Pearce EL, Pearce EJ. 2013. Metabolic Pathways in Immune Cell Activation and  
179 Quiescence. *Immunity* 38:633–643.
- 180 8. Asch DA, Sheils NE, Islam N, Chen Y, Werner RM, Buresh J, Doshi JA. 2020. Variation  
181 in US Hospital Mortality Rates for Patients Admitted With COVID-19 During the First 6  
182 Months of the Pandemic 19104:1–8.
- 183 9. Bellan M, Patti G, Hayden E, Azzolina D, Pirisi M, Acquaviva A, Aimaretti G, Valletti  
184 PA, Angilletta R, Arioli R, Avanzi GC, Avino G, Balbo PE, Baldon G, Baorda F, Barbero  
185 E, Baricich A, Barini M, Adesi FB, Battistini S, Beltrame M, Bertoli M, Bertolin S,  
186 Bertolotti M, Betti M, Bobbio F, Boffano P, Boglione L, Borrè S, Bruccoli M, Calzaducca  
187 E, Cammarata E, Cantaluppi V, Cantello R, Capponi A, Carriero A, Casciaro FG, Castello  
188 LM, Ceruti F, Chichino G, Chirico E, Cisari C, Cittone MG, Colombo C, Comi C, Croce  
189 E, Daffara T, Danna P, Corte F Della, Vecchi S De, Dianzani U, Benedetto D Di, Esposto  
190 E, Faggiano F, Falaschi Z, Ferrante D, Ferrero A, Gagliardi I, Gaidano G, Galbiati A,  
191 Gallo S, Garavelli PL, Gardino CA, Garzaro M, Gastaldello ML, Gavelli F, Gennari A,  
192 Giacomini GM, Giacone I, Via VG, Giolitti F, Gironi LC, Gramaglia C, Grisafi L, Inserra  
193 I, Invernizzi M, Krenqli M, Labella E, Landi IC, Landi R, Leone I, Lio V, Lorenzini L,  
194 Marzari L, Marzullo P, Mennuni M, Montabone C. 2020. Fatality rate and predictors of  
195 mortality in an Italian cohort of hospitalized COVID □ 19 patients. *Sci Rep* 1–10.
- 196 10. Blasco H, Bessy C, Plantier L, Lefevre A, Piver E, Bernard L, Marlet J, Stefic K, Benz-de  
197 Bretagne I, Cannet P, Lumbu H, Morel T, Boulard P, Andres CR, Vourc’h P, Hérault O,  
198 Guillon A, Emond P. 2020. The specific metabolome profiling of patients infected by  
199 SARS-COV-2 supports the key role of tryptophan-nicotinamide pathway and cytosine  
200 metabolism. *Sci Rep* 10:1–12.

- 201 11. Thomas T, Stefanoni D, Reisz JA, Nemkov T, Bertolone L, Francis RO, Hudson KE,  
202 Zimring JC, Hansen KC, Hod EA, Spitalnik SL, D’Alessandro A. 2020. COVID-19  
203 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and  
204 renal status. *JCI Insight* 5.
- 205 12. Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, Quan S, Zhang F, Sun R, Qian L, Ge W, Liu  
206 W, Liang S, Chen H, Zhang Y, Li J, Xu J, He Z, Chen B, Wang J, Yan H, Zheng Y, Wang  
207 D, Zhu J, Kong Z, Kang Z, Liang X, Ding X, Ruan G, Xiang N, Cai X, Gao H, Li L, Li S,  
208 Xiao Q, Lu T, Zhu YJ, Liu H, Chen H, Guo T. 2020. Proteomic and Metabolomic  
209 Characterization of COVID-19 Patient Sera. *SSRN Electron J*  
210 <https://doi.org/10.1101/2020.04.07.20054585>.
- 211 13. Lawler NG, Gray N, Kimhofer T, Boughton B, Gay M, Yang R, Morillon A-C, Chin S-T,  
212 Ryan M, Begum S, Bong SH, Coudert JD, Edgar D, Raby E, Pettersson S, Richards T,  
213 Holmes E, Whiley L, Nicholson JK. 2021. Systemic Perturbations in Amine and  
214 Kynurenine Metabolism Associated with Acute SARS-CoV-2 Infection and Inflammatory  
215 Cytokine Responses. *J Proteome Res* <https://doi.org/10.1021/acs.jproteome.1c00052>.
- 216 14. Henry BM, Helena M, Oliveira S De, Benoit S. 2020. Hematologic , biochemical and  
217 immune biomarker abnormalities associated with severe illness and mortality in  
218 coronavirus disease 2019 ( COVID-19 ): a meta-analysis 58:1021–1028.
- 219 15. Xia J, Wishart DS. 2011. Web-based inference of biological patterns, functions and  
220 pathways from metabolomic data using MetaboAnalyst. *Nat Protoc* 6:743–760.
- 221 16. Liu P-S, Wang H, Li X, Chao T, Teav T, Christen S, Di Conza G, Cheng W-C, Chou C-H,  
222 Vavakova M, Muret C, Debackere K, Mazzone M, Huang H-D, Fendt S-M, Ivanisevic J,

- 223 Ho P-C. 2017.  $\alpha$ -ketoglutarate orchestrates macrophage activation through metabolic and  
224 epigenetic reprogramming. *Nat Immunol* 18:985–994.
- 225 17. Martinez FO, Combes TW, Orsenigo F, Gordon S. 2020. Monocyte activation in systemic  
226 Covid-19 infection: Assay and rationale. *EBioMedicine* 59:102964.
- 227 18. Cengiz M, Uysal BB, Ikitimur H, Ozcan E, Aktepe E, Yavuzer H, Yavuzer S. 2020. Effect  
228 of oral L -Glutamine supplementation on Covid-19 treatment 33:24–31.
- 229 19. Obayan AOE. 2021. Infectious Diseases and Epidemiology Overview of the Rationale for  
230 L-Glutamine Treatment in Moderate-Severe COVID-19 Infection Proposed Flowchart of  
231 In fl ammatory Response In COVID-19 Infec □ on 7:1–7.
- 232 20. Ware LB, Magarik JA, Wickersham N, Cunningham G, Rice TW, Christman BW,  
233 Wheeler AP, Bernard GR, Summar ML. 2013. Low plasma citrulline levels are associated  
234 with acute respiratory distress syndrome in patients with severe sepsis 1–8.
- 235 21. Reyes AA, Karl IE, Klahr S. 1994. Role of arginine in health and in renal disease. *Am J*  
236 *Physiol Physiol* 267:F331–F346.
- 237 22. Lee GK, Park HJ, Macleod M, Chandler P, Munn DH, Mellor AL. 2002. Tryptophan  
238 deprivation sensitizes activated T cells to apoptosis prior to cell division. *Immunology*  
239 107:452–460.
- 240 23. Greene LI, Bruno TC, Christenson JL, D&#039;Alessandro A, Culp-Hill R, Torkko K,  
241 Borges VF, Slansky JE, Richer JK. 2019. A Role for Tryptophan-2,3-dioxygenase in CD8  
242 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient  
243 Plasma. *Mol Cancer Res* 17:131 LP – 139.

- 244 24. Minhas PS, Liu L, Moon PK, Joshi AU, Dove C, Mhatre S, Contrepois K, Wang Q, Lee  
245 BA, Coronado M, Bernstein D, Snyder MP, Migaud M, Majeti R, Mochly-Rosen D,  
246 Rabinowitz JD, Andreasson KI. 2019. Macrophage de novo NAD<sup>+</sup> synthesis specifies  
247 immune function in aging and inflammation. *Nat Immunol* 20:50–63.
- 248 25. Van Gool F, Gallí M, Gueydan C, Kruys V, Prevot P-P, Bedalov A, Mostoslavsky R, Alt  
249 FW, De Smedt T, Leo O. 2009. Intracellular NAD levels regulate tumor necrosis factor  
250 protein synthesis in a sirtuin-dependent manner. *Nat Med* 15:206–210.
- 251 26. Pang Z, Zhou G, Chong J, Xia J. 2021. Comprehensive meta-analysis of covid-19 global  
252 metabolomics datasets. *Metabolites* 11:1–14.
- 253 27. Zangerle R, Kurz K, Neurauter G, Kitchen M, Sarcletti M, Fuchs D. 2010. Increased  
254 blood phenylalanine to tyrosine ratio in HIV-1 infection and correction following effective  
255 antiretroviral therapy. *Brain Behav Immun* 24:403–408.
- 256 28. Ploder M, Neurauter G, Spittler A, Schroecksnadel K, Roth E, Fuchs D. 2008. Serum  
257 phenylalanine in patients post trauma and with sepsis correlate to neopterin  
258 concentrations. *Amino Acids* 35:303–307.
- 259 29. Würtz P, Havulinna AS, Soininen P, Tynkkynen T, Prieto-Merino D, Tillin T, Ghorbani  
260 A, Artati A, Wang Q, Tiainen M, Kangas AJ, Kettunen J, Kaikkonen J, Mikkilä V, Jula A,  
261 Kähönen M, Lehtimäki T, Lawlor DA, Gaunt TR, Hughes AD, Sattar N, Illig T, Adamski  
262 J, Wang TJ, Perola M, Ripatti S, Vasan RS, Raitakari OT, Gerszten RE, Casas J-P,  
263 Chaturvedi N, Ala-Korpela M, Salomaa V. 2015. Metabolite profiling and cardiovascular  
264 event risk: a prospective study of 3 population-based cohorts. *Circulation* 2015/01/08.  
265 131:774–785.

266 30. Luo P, Liu D, Li J. 2021. Epinephrine use in COVID-19: friend or foe? Eur J Hosp Pharm  
267 28:e1 LP-e1.

268

## 269 **Figures**

270 **Figure 1. Targeted metabolomic analysis of longitudinal serum samples of hospitalized**  
271 **COVID-19 patients.** (A) Heatmap and hierarchical clustering of top 22 significantly altered  
272 metabolites. Each column represents one sample: (0, green) - samples collected in the acute  
273 phase, (1, red) - samples collected during the recovery phase, each row conforms to a specific  
274 metabolite expressed in normalized, log transformed concentration value. (B) Principal  
275 component analysis showing clear discrimination of samples collected in the acute and recovery  
276 phases of infection based on the obtained metabolite profiles. (C) Scatter plot representing the  
277 most relevant metabolic pathways from KEGG library arranged by adjusted p-values (obtained  
278 by Global Test pathway enrichment analysis) on Y-axis, and pathway impact values (from  
279 pathway topology analysis) on X-axis. The node color is based on its p-value and the node radius  
280 is determined based on their pathway impact values. (D) Boxplots showing the normalized levels  
281 of the most functionally relevant metabolites during the acute phase (0) and the recovery phase  
282 (1) of the infection, described as the minimum value, the first quartile, the median, the third  
283 quartile, and the maximum value with the black dots representing each sample.

284

285

286

287

288

289 **Tables**

290 Table 1. Serum metabolites showing significantly altered levels comparing measures obtained  
291 during the acute phase and recovery phase of the disease.

---

<b>Compound</b>	<b>Fold change</b>	<b>False discovery rate</b>
L-Glutamine	0.72	5.71E-08
Citrulline	0.48	9.16E-08
3-Hydroxy-DL-Kynurenine	10.51	6.79E-07
L-Phenylalanine	1.33	6.79E-07
L-Methionine	1.47	1.62E-06
Isovalerylcarnitine	2.01	1.78E-06
4-Hydroxyproline	0.42	1.99E-06
Kynurenine	1.71	2.67E-06
L-Asparagine	1.51	3.88E-05
L-Glutamic acid	1.65	4.61E-05
L-Valine	1.26	7.73E-05
Carnitine	1.25	8.90E-05
L-Tryptophan	0.83	2.87E-04
L-Tyrosine	1.14	2.87E-04
L-Threonine	1.45	2.15E-03
L-Proline	0.86	3.23E-03
Taurine	1.36	6.01E-03

Ornithine	1.37	9.45E-03
L-Lysine	1.08	1.15E-02
L-Isoleucine	1.21	1.25E-02
L-Acetylcarnitine	1.21	2.34E-02
L-Octanoylcarnitine	0.75	3.85E-02

---

292

293 **Appendixes**

294 Text S1. Detailed Methods Description.

295 Table S1. Characteristics of the study participants.

296 Table S2. Data matrix with quantified metabolite concentrations for targeted compounds,  
297 determined by ultra-performance liquid chromatography-mass spectrometry.

298 Table S3. Significant pathways based on enrichment procedures.

